tiprankstipranks
Trending News
More News >
Nakanishi (JP:7716)
:7716
Advertisement

Nakanishi (7716) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7716

Nakanishi

(Frankfurt:7716)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
¥2,289.00
▲(10.37% Upside)
Nakanishi's strong financial performance, characterized by robust revenue growth and efficient cash flow management, is the primary driver of its stock score. Technical analysis indicates a neutral trend with potential upward momentum. However, the stock's high P/E ratio suggests it may be overvalued, which slightly offsets the positive financial indicators.

Nakanishi (7716) vs. iShares MSCI Japan ETF (EWJ)

Nakanishi Business Overview & Revenue Model

Company DescriptionNakanishi Inc. manufactures and sells dental, industrial, and medical products worldwide. The company offers turbines; clinical micromotors; contra-angles; and built-in, mobile dentistry, oral hygiene, endodontic, surgical, dental laboratory, and hygiene and maintenance products. It also offers motor spindles, and micro gridlers and tools. The company serves automotive, micromechanics, electronics, medical, die/mold, aerospace, and energy industries. Nakanishi Inc. was founded in 1930 and is headquartered in Kanuma, Japan.
How the Company Makes MoneyNakanishi Inc. generates revenue through the sale of its precision instruments and equipment to dental professionals and industrial clients globally. The company's revenue streams are largely driven by the production and distribution of dental handpieces and related products, which are essential tools in dental practices and surgeries. Additionally, Nakanishi capitalizes on its industrial precision tools, serving sectors such as electronics and automotive manufacturing. The company's earnings are supported by its strong global distribution network and strategic partnerships with local distributors and dental equipment manufacturers, enabling it to reach a wide customer base. By continuously investing in research and development, Nakanishi maintains its competitive edge, ensuring a steady flow of innovative products that meet the evolving needs of its clients.

Nakanishi Financial Statement Overview

Summary
Nakanishi exhibits strong financial health with significant revenue growth and efficient cash flow management. The company maintains a robust balance sheet with low leverage, though the recent decline in net income impacts profitability metrics.
Income Statement
85
Very Positive
Nakanishi shows strong revenue growth with a notable increase of 29.05% from 2023 to 2024, indicating a healthy business expansion. The gross profit margin is robust at 57.66% for 2024, suggesting efficient production and cost management. Despite a decline in net income from 2023 to 2024, the net profit margin remains solid at 11.13%. EBIT and EBITDA margins are strong at 18.94% and 26.55% respectively, showcasing operational efficiency.
Balance Sheet
78
Positive
Nakanishi maintains a strong equity base with an equity ratio of 76.55% in 2024, indicating financial stability and low leverage. The debt-to-equity ratio is low at 0.15, reflecting prudent debt management. However, there is a significant decline in net income impacting the ROE, which stands at 7.08% for 2024, down from previous years.
Cash Flow
82
Very Positive
The company demonstrates impressive free cash flow growth of 287.01% from 2023 to 2024, highlighting effective cash generation. The operating cash flow to net income ratio is 1.78, indicating strong cash conversion. The free cash flow to net income ratio is 1.17, reflecting efficient capital expenditure management. However, the operating cash flow growth is moderate compared to revenue growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue77.42B77.04B59.69B48.67B44.86B33.06B
Gross Profit44.12B44.42B36.09B31.22B27.30B19.73B
EBITDA19.60B19.59B32.30B19.40B15.80B10.88B
Net Income5.64B8.58B22.80B12.47B10.10B6.46B
Balance Sheet
Total Assets151.83B158.30B140.71B102.15B94.46B82.47B
Cash, Cash Equivalents and Short-Term Investments44.95B47.11B32.65B36.18B37.41B33.67B
Total Debt20.27B18.73B11.67B480.80M100.00M100.00M
Total Liabilities36.80B37.10B27.51B11.13B11.54B6.20B
Stockholders Equity115.03B121.19B113.19B91.02B82.92B76.27B
Cash Flow
Free Cash Flow0.0010.05B2.60B3.78B9.62B7.99B
Operating Cash Flow0.0015.30B8.56B7.76B11.97B9.18B
Investing Cash Flow0.00-7.94B-19.15B-6.31B-4.15B-1.38B
Financing Cash Flow0.00598.51M3.41B-6.11B-3.97B-2.69B

Nakanishi Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2074.00
Price Trends
50DMA
2009.00
Positive
100DMA
1930.86
Positive
200DMA
2086.08
Negative
Market Momentum
MACD
20.81
Positive
RSI
48.60
Neutral
STOCH
62.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7716, the sentiment is Negative. The current price of 2074 is below the 20-day moving average (MA) of 2093.10, above the 50-day MA of 2009.00, and below the 200-day MA of 2086.08, indicating a neutral trend. The MACD of 20.81 indicates Positive momentum. The RSI at 48.60 is Neutral, neither overbought nor oversold. The STOCH value of 62.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7716.

Nakanishi Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
144.86B17.886.62%3.62%2.72%-6.31%
76
Outperform
200.56B15.4810.15%2.52%7.28%1.72%
75
Outperform
125.12B22.9412.01%3.07%5.82%-20.09%
73
Outperform
¥177.22B34.454.39%2.53%10.98%-76.45%
72
Outperform
69.83B17.2610.12%2.50%6.82%-1.08%
57
Neutral
250.92B44.052.03%2.08%8.83%-40.24%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7716
Nakanishi
2,070.00
-387.98
-15.78%
DE:5FA
Nipro
8.75
0.85
10.76%
PBHDF
Paramount Bed Holdings Co
18.48
1.36
7.94%
SHHPF
Ship Healthcare Holdings
17.38
2.47
16.57%
JP:7730
Mani, Inc.
1,270.00
-499.62
-28.23%
JP:7979
Shofu Inc.
1,967.00
-395.13
-16.73%

Nakanishi Corporate Events

Nakanishi Inc. Updates on Share Repurchase Program
Sep 1, 2025

Nakanishi Inc. announced the status of its share repurchase program, which was resolved in a Board of Directors meeting on February 12, 2025. The company has repurchased 1,277,700 shares at a cost of JPY 2,652,962,400 as of August 31, 2025, with plans to repurchase up to 2,000,000 shares by the end of the year. This move is part of a strategic effort to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (JP:7716) stock is a Buy with a Yen2340.00 price target. To see the full list of analyst forecasts on Nakanishi stock, see the JP:7716 Stock Forecast page.

Nakanishi Inc. Reports Decline in Q2 2025 Earnings Amid Slight Sales Growth
Aug 8, 2025

Nakanishi Inc. reported a decrease in its financial performance for the second quarter of 2025, with net sales slightly increasing by 1.6% but operating income and ordinary income declining by 8.4% and 34.1% respectively compared to the previous year. The company maintained a strong equity ratio of 76.0% despite a reduction in total assets and net assets, and it announced a forecasted increase in annual dividends, reflecting a cautious yet optimistic outlook for the remainder of the year.

Nakanishi Inc. Updates on Share Repurchase Program
Aug 1, 2025

Nakanishi Inc. announced the status of its share repurchase program, initially resolved in February 2025. As of July 31, 2025, the company repurchased 1,084,100 shares at a cost of JPY 2,253,016,800, with plans to repurchase up to 2,000,000 shares by the end of the year. This move could impact the company’s financial structure and shareholder value.

Nakanishi Inc. Updates on Share Repurchase Program
Jul 1, 2025

Nakanishi Inc. announced the status of its share repurchase program, resolved in February 2025, aiming to repurchase up to 2,000,000 common shares by the end of December 2025. As of June 30, 2025, the company has repurchased 1,084,100 shares, reflecting a significant step in its financial strategy, impacting its market positioning and shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 13, 2025